Agios to focus on developing and commercializing innovative treatments for genetically defined diseases and sell its oncology business to Servier for up to $2 billion plus royalties

Agios Pharmaceuticals, Inc.,a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company. Agios will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash and $200 million in a potential future milestone payment for vorasidenib, as well as 5% royalties on U.S. net sales of Tibsovo (ivosidenib tablets) from transaction close through loss of exclusivity and 15% royalties on U.S. net sales of vorasidenib from first commercial sale through loss of exclusivity. The transaction includes the transfer of Agios’ oncology portfolio and associated employees, including its marketed medicine Tibsovo which is approved in the U.S. as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML) and for adults with newly diagnosed IDH1-mutant AML who are greater than 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Tibsovo is also under investigation in two Phase III combination trials in newly diagnosed AML, and as a potential treatment for previously treated IDH1-mutant cholangiocarcinoma and IDH1-mutant myelodysplastic syndrome (MDS). Servier will also acquire Agios’ co-commercialization responsibilities for Bristol Myers Squibb’s IDHIFA (enasidenib) and conduct certain clinical development activities within the IDHIFA development program. In addition, the transaction includes Agios’ oncology pipeline and clinical programs, including vorasidenib, an investigational, brain-penetrant, dual inhibitor of mutant IDH1 and IDH2 which is currently being studied in the registration-enabling Phase III INDIGO study in patients with IDH-mutant low-grade glioma; AG 270, an investigational first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor being evaluated in combination with taxanes in patients with methylthioadenosine phosphorylase (MTAP)-deleted non-small cell lung cancer and pancreatic cancer; AG 636, a novel inhibitor of dihydroorotate dehydrogenase (DHODH); and Agios’ oncology research programs.